Dilip Shanghvi – Founding Sun Pharmaceuticals and Pharma Leadership

Dilip Shanghvi is the Founder and Managing Director of India’s most valuable listed pharmaceutical company, Sun Pharmaceutical Industries, while also heading Sun Pharma Advanced Research.

Shanghvi was raised in a family of wholesale drug distributors. In 1982 he started Sun Pharmaceutical with an initial capital of Rs 10,000. Today the company generates billions in revenues both domestically and internationally.

How He Became a Billionaire

Dilip Shanghvi took Sun Pharmaceutical Industries from an Indian firm into one of the five biggest generic-drug producers worldwide through a series of acquisitions. He began expanding into the US market by purchasing Detroit-based Caraco Pharmaceuticals in 1997 – giving access to one of the world’s biggest drug markets and distribution channels – before going on to purchase 13 drugmakers such as Taro Pharmaceutical Industries and Ranbaxy Laboratories to become a key player here.

Shanghvi orchestrated a $3.2 billion buyout of Ranbaxy Pharma Ltd in 2015 to take control of India’s most valuable listed pharma outfit and become India’s richest man. Today, two thirds of his firm’s $5.3 billion annual revenue come from overseas markets while biosimilar drugs have also been invested in to reduce patient costs; photos of Shrinathji are prominently displayed throughout his factories and offices as proof.

Shanghvi stands out from other promoters by not overtly following the stock market and actively looking for ways to raise share prices, instead opting to focus on running his business rather than looking for ways to make its shares rise. His low-profile management style helps limit speculation regarding his personal wealth despite being one of India’s wealthiest people.

Forbes estimates the current net worth of this 63-year-old is estimated at about $16 billion, as his company provides generic drugs, vaccines, contact lenses and animal health products with its combined revenue surpassing Aurobindo Pharma Ltd by more than twofold.

Shanghvi holds stakes in Mumbai-based wind turbine manufacturer Suzlon Energy Ltd. and 13% ownership in Jindal Stainless Steel Ltd, India’s fourth-largest steelmaker. In 2016, he received India’s fourth-highest civilian award: Padma Shri from its government.

Shanghvi will be an interesting one to keep an eye on as he expands his global footprint. Already established in China – the second-biggest drug market globally – he plans on manufacturing local products within three years, as well as recently releasing an anti-diarrhea pill in the US where pricing wars have seen their rivals lose ground due to aggressive competition.

His Business Strategy

As a boy, Shanghvi would watch his father work hard in their small wholesale drug shop at Dawa Bazar market in Calcutta (Kolkata). Now 68 years old and worth billions, this former child prodigy from Dawa Bazar heads a global generics giant that ranks fourth-largest specialty pharmaceutical company by revenue. His company was built through acquisitions of underperforming and troubled drugmakers and their subsequent incorporation within his organization; moreover he ventured into biosimilars (drugs which mimic or replicate the effects of existing biologic drugs), creating new businesses which compete fiercely within industry boundaries despite fiercely competitive markets he also ventured into biosimilars (drugs which mimic or replicate existing biologic drugs in order to create highly competitive businesses that mimic or replicate effects from existing biologic drug treatments).

He has also ventured abroad in order to tap new markets, selling drugs in Europe, Latin America and Africa as well as the US market where Sun Pharma holds the top market share among Indian pharmaceutical firms with largest overseas revenue and market share over Aurobindo Pharma – their nearest domestic rival in this regard.

Shanghvi’s success lies in his willingness to invest in the future–even when this requires taking a temporary hit on his bottom line in the short term. That strategy has paid dividends: in their latest fiscal year, their company’s consolidated net profit increased 159% year over year to Rs8,474 crore-despite investing heavily in building capacity in both India and America which will take time for fruits of labor to appear.

Sun Pharma’s expansion in foreign markets, particularly the US and China, has helped it weather recent price wars in its domestic market – one where Sun Pharma holds a leadership position. Furthermore, its acquisition of Ranbaxy Laboratories for $825 million made them one of the five biggest generic drugmakers globally and secured them an important spot within China’s $160 billion pharmaceutical market.

Shanghvi still needs to demonstrate whether he can replicate his success in China, where his profits have lagged those in the US. Yet this man who once borrowed Rs 10,000 to establish his drugmaker now has enough resources available to him to seize any opportunity that arises.

His Leadership Style

Shanghvi led Sun Pharmaceuticals with an unwavering vision and strong moral character. He promoted an atmosphere of integrity and discipline within his workplace, inspiring employees to follow suit. Shanghvi believed in giving back to the community, with this philosophy evident in his business decisions. His impeccable leadership style revolutionized generic drug manufacturing while leaving an indelible mark on Indian entrepreneurship.

Shanghvi understood the power of teamwork was essential to company success, so he sought out individuals who shared his vision and passion for creating successful businesses, to form an environment conducive to innovation and growth. By surrounding himself with these like-minded individuals he managed to establish an environment conducive to both innovation and growth within his workforce.

His leadership style also included acquisitions and international expansion – a successful strategy which enabled him to break into the lucrative US market while expanding their share in global generic drug sales. Furthermore, he invested heavily in research and development while collaborating with leading institutions and scientists worldwide to advance pharmaceutical advancement worldwide.

Shanghvi remains grounded despite all his accomplishments and accolades, working to improve Sun Pharmaceuticals products while adhering to high ethical standards in business. He serves as an inspiration to aspiring entrepreneurs; his story serves as proof that with drive and commitment anyone can reach any goal they set themselves.

Shanghvi takes great pleasure in spending his leisure time with his family; both his daughter and son are involved with Sun Pharmaceuticals’ family business. While Shanghvi prefers keeping details about his personal life out of public view, it is well known that he enjoys reading up-to-date industry trends and advances; likely contributing to his creative thinking skills and strategic decision-making at Sun Pharmaceuticals.

His Personality

Dilip Shanghvi possesses a firm grasp on what his business stands for and knows how to manage people effectively. While still hands-on, he allows his top team members to take control of certain things – for instance, several years ago he would attend new product meetings himself, according to former colleagues; these days they are handled by country heads. Furthermore, Dilip is known for being an excellent listener – always on the lookout for lessons Sun Pharma can take away from competitors.

He possesses an exceptional talent for recognizing talent. That’s why his appointment of Israel Makov as chairman was widely seen as a masterstroke – his sharp analytical skills will benefit the company, according to another executive who has worked closely with Makov.

Shanghvi has developed his grit and determination through his upbringing, instilled by both parents. Shantilal, as a medicine merchant, instilled values of hard work and entrepreneurialism early in his son. Additionally, Kumud played an influential part in molding him.

Shanghvi graduated from University of Calcutta at 27 and moved to Mumbai with only Rs 10,000 to launch Sun Pharmaceuticals – initially with five products that included Lithosun for mental disorders as well as a factory located in Vapi, Gujarat.

At first, Shanghvi faced stiff competition from multinational competitors with deep pockets and established brand names. To remain profitable and stay relevant in his market place, he realized it was imperative to distinguish his products by emphasizing quality over quantity, investing in research, and adopting innovative strategies such as printing both English and Hindi versions of product names on packaging to increase brand recognition and loyalty.

Sun Pharmaceuticals grew at an astounding 30-percent compound annual rate over two decades. Under Shanghvi, Sun Pharmaceuticals achieved unprecedented heights of growth during this time, becoming India’s biggest drugmaker and reaching unprecedented levels of profitability. He focused on improving efficiency and building management capability at all levels as well as creating therapy-focussed divisions to target specific diseases; this helped cultivate stronger relationships between doctors and the company as well as increase sales volumes.